Verekitug
Severe Asthma
Key Facts
About Upstream Bio
Upstream Bio is focused on developing verekitug, the only known clinical-stage antagonist of the TSLP receptor, to address chronic respiratory diseases driven by inflammation. The company has completed Phase 2 trials in severe asthma and CRSwNP and has an ongoing Phase 2 trial in COPD. Led by an experienced team with deep industry and clinical expertise, Upstream Bio aims to provide a differentiated, upstream therapeutic approach for patients underserved by current standards of care.
View full company profileAbout Upstream Bio
Upstream Bio is focused on developing verekitug, the only known clinical-stage antagonist of the TSLP receptor, to address chronic respiratory diseases driven by inflammation. The company has completed Phase 2 trials in severe asthma and CRSwNP and has an ongoing Phase 2 trial in COPD. Led by an experienced team with deep industry and clinical expertise, Upstream Bio aims to provide a differentiated, upstream therapeutic approach for patients underserved by current standards of care.
View full company profileAbout Upstream Bio
Upstream Bio is focused on developing verekitug, the only known clinical-stage antagonist of the TSLP receptor, to address chronic respiratory diseases driven by inflammation. The company has completed Phase 2 trials in severe asthma and CRSwNP and has an ongoing Phase 2 trial in COPD. Led by an experienced team with deep industry and clinical expertise, Upstream Bio aims to provide a differentiated, upstream therapeutic approach for patients underserved by current standards of care.
View full company profileTherapeutic Areas
Other Severe Asthma Drugs
| Drug | Company | Phase |
|---|---|---|
| Nucala (mepolizumab) | GSK plc | Approved |
| GB-0895 | Generate Biomedicines | Phase 3 |